Medulloblastomas exhibit an array of diverse cytogenetic abnormalities. To evaluate the signi®cance of epigenetic rather than genetic lesions in medulloblastomas and other primitive neuroectodermal tumors (PNETs) of the childhood CNS we performed a systematic analysis of gene speci®c and global methylation. Methylationspeci®c PCR detected no methylation for p15
Introduction
The survival rates for children with medulloblastomas (MBs) have been steadily increasing over the past 10 years (Packer, 1999) . Nevertheless, a residual syndrome comprising developmental delay due to hormonal dysfunctions and intellectual de®cits secondary to neuronal damage often aects survivors (Mulhern et al., 1999) . Furthermore, a tumor relapse is only rarely survived (David et al., 1997) . These data indicate the need for re®ned diagnostic and therapeutic approaches, potentially achievable through a better understanding of the molecular pathology of these neoplasms. Recently molecular markers such as ampli®cation of the MYC gene or the expression level of the receptor tyrosine kinase TrkC have been proposed as prognostic markers for the staging of childhood MBs (Grotzer et al., 2000; Scheurlen et al., 1998) .
MBs are classi®ed as Primitive Neuroectodermal Tumors (PNETs), a genetically rather heterogeneous group of neoplasias (Rorke et al., 1997) . While a small subgroup of MBs seems to be characterized by mutations in the human homologue of the drosophila segment polarity gene PTCH1, no clear molecular pathway has been de®ned for the origin of the majority of MBs (Zurawel et al., 2000) . Recent studies using Comparative Genome Hybridization (CGH) demonstrated loss of genetic material from chromosomes 8p, 10q, 11, 16q, 17p (in up to 50%) and 22; gains were detected for 17q and 7 and ampli®cations were seen in 5p15.3 and 11q22.3 (Reardon et al., 1997; Russo et al., 1999) . The aected genes at the respective loci remain to be elucidated.
According to contemporary models of the evolution of cancer, accumulating genetic lesions in growth promoting oncogenes and growth inhibiting tumor suppressor genes are responsible for tumorigenesis. Very recently DNA methylation has been shown to in¯uence the transcriptional activity of tumor suppressor genes in a variety of neoplasias (Baylin and Herman, 2000) . There is mounting evidence that promoter methylation of growth regulatory genes can inhibit transcription either in combination with dele-tions or mutations of one allele and methylation on the other allele or by biallelic methylation (Jones and Laird, 1999) .
We addressed the issue of promoter methylation in MBs/PNETs by studying the previously identi®ed methylation targets p15
INK4B
, p16
INK4A
, VHL, TP53 and ECAD using Methylation-speci®c PCR (Ms-PCR) . Since these genes demonstrated only minor methylation aberrations we applied the methylation scanning capabilities of Restriction Landmark Genomic Scanning (RLGS) to search for novel methylation targets. We detected widespread global methylation changes in primary tumors and to a higher degree in cell line. Rigorous statistical analysis of survival data suggests a correlation between outcome and methylation status of several CpG islands. DNA methylation thus promises to be a valuable prognostic marker in MBs/PNETs and an important mechanism contributing to carcinogenesis of MBs/PNETs.
Results

Methylation of p15 INK4B
INK4A and E-cadherin is a rare event in MBs/PNETs
To determine whether promoter methylation is a contributing factor to the development of MBs we employed Ms-PCR and examined the methylation status of p15
INK4B
INK4A
, von Hippel Lindau (VHL), TP53 and E-cadherin (ECAD) in 20 MBs, three stPNETs, ®ve MB cell lines and ®ve normal cerebella (see Table 1 for summary). Interestingly ECAD was found partially methylated in three primary tumors (MB2, stPNET22, MB28) and two cell lines (D341 Med, MHH-PNET-5). The cell line D283Med showed complete methylation. Examining p16 INK4A methylation we found the majority of the samples unmethylated, while most samples and normal cerebellum also showed a weak band for the methylated sequence (see Figure 1a) . Four samples exhibited predominant methylation (MB15, MB27, stPNET22 and MHH-MED-1). The cell lines Daoy, MHH-PNET-5 and the primary MB26 showed complete methylation. To con®rm the identity of PCR products, bands of all ®ve MB cell lines and tumor MB15 were cloned and ®ve clones each sequenced. All CG sites remained unchanged (methylated) while PCR products generated with primers for unmethylated DNA from D283 Med, D341 Med and MHH-MED-1 showed complete conversion of all CG dinucleotides to TG dinucleotides (data not shown). Figure 1b) . Expression of p16 in Daoy cells could not be re-established by treatment with the demethylating agent 5'-aza-2'-deoxycytidine (data not shown).
Expression of the p16 protein in MBs was also analysed by immunohistochemistry with a monoclonal antibody. Control tissues were normal cerebella of a newborn (2 weeks) and an infant (5 months). Normal bladder tissue from an 8 year old served as a positive control; 11 of the 16 primary tumors had also been tested by Ms-PCR. While the positive control (normal bladder), showed positive staining for p16 protein, neither normal cerebellum nor any of the tumors were positive (data not shown). Since loss of genomic material could be another means of silencing the expression of a gene, we analysed several samples and the cell lines by SSCP. For both cell lines, which lacked expression of p16 (Daoy, MHH-PNET-5) by RT ± PCR, neither exon 1 nor 2 could be ampli®ed, indicating loss of genomic material of this gene. Interestingly stPNET22, MB15, MB26 and MB27 showed aberrant methylation but no loss of genomic material (see Table 1 ). Unfortunately no RNA was available for these tumors to further evaluate expression.
Global CpG island methylation is a common epigenetic aberration in primary MB/PNETs and derived cell lines
The ®nding of promoter methylation in known tumor suppressor genes indicates that methylation may play a role in tumor progression in MB/PNETs. However, these studies on selected genes do not allow an estimate of the overall contribution of methylation to tumorigenesis. To assess genome wide methylation patterns, we chose the methylation scanning properties of RLGS for further experiments. A total of 17 MBs, ®ve stPNETs and ®ve MB cell lines were examined. A minimum total of 30 dierent DNA fragments were lost from RLGS tumor pro®les and thus methylated when normal tissues (cerebella, matching peripheral blood lymphocytes) were compared to MB/PNETs (see Figure 2 for an example of methylation in RLGS fragment 3D9 and Table 2 ). Stringent criteria were applied as described previously . Methylation ranged from 3 ± 21 CpG islands in individual MBs and from 9 ± 17 in stPNETs (1576 analysed CpG islands). None of the tumors showed a normal methylation pattern comparable to matched PBL or to dierent normal cerebella. The majority of tumors exhibited between 10 and 14 methylation events (MBs, seven, stPNETs three). In the lower methylation group we found four MBs and one stPNET with 5 ± 9 methylated CpG islands and three MBs exhibited 3 ± 4 methylated sequences. Of the 30 methylated sequences one was methylated in only one MB and one stPNET (3C16), ®ve CpG islands were methylated in two MBs each and 11 in two stPNETs. Five CpG islands (2C53, 3D35, 2C35, 4F8 and 2E61) were methylated in over 50% of the examined MBs. The same is true for ten CpG islands in the PNET group (see Table 2 ). The Southern hybridization using a probe derived from the CpG island 3D09 as a probe. Samples were all digested with EcoRV and with or without NotI. For MBs 12, 17, 19 the ®rst two lanes out of three each represent normal PBL cleaved with EcoRV alone and then with NotI. Lane three for these samples is the corresponding tumor cleaved with both enzymes. While tumor MB17 is not clearly assessable, MB12, 26 and 6 demonstrate partial methylation with a shift to the larger fragment (indicative of incomplete cleavage with the methylation sensitive enzyme NotI). MB19, 8 and PNET21 demonstrate complete methylation with no detectable NotI ± EcoRV fragment. The partial methylation in the other tumor samples could be due to contaminating normal cerebellum DNA in the homogenized tissue specimen highest frequency methylation events in MBs were 15, out of 1576 analysable, CpG islands. For stPNETs one CpG island was methylated in four of ®ve stPNETs (4G78). A total of 198 fragments were methylated in the examined cell lines. We detected 85 methylation events in the cell line MHH-MED-1, 80 in MHH-PNET-5, 69 in D341 Med, 37 in D283Med and 28 in Daoy.
Intriguingly, the rank-correlation analysis of the DNA fragment loss patterns between primary tumors and cell lines demonstrated that Daoy, the cell line with the least methylation events among the cell lines, showed the strongest correlation (P50.006) with primary tumors. Daoy was followed by D283 Med (P=0.096) and D341 Med (P=0.025), while MHH-MED-1 (P=0.87) and MHH-PNET-5 (P=0.68) showed the least similar methylation patterns when compared to primaries and the cell lines with the highest number of methylated DNA fragments. Extrapolated to the whole human genome with an approximate number of 29 000 CpG islands, we estimate that up to 1800 CpG islands (*6%) are methylated in cell lines, while in primary tumors up to 290 CpG islands (*1%) are methylated (Venter et al., 2001; Consortium IHGS, 2001) . Table 2 gives a summary of the hypermethylated CpG islands separated into MBs, stPNETs and cell lines.
Two DNA fragments (2E61 and 3B26) are methylated only in MBs (speci®c targets) while all others were methylated in both tumor types as well as in MB cell lines (shared targets). DNA fragment 2C53 e.g. was methylated in 88.2% of MBs, 60% of stPNETs and in 80% of the cell lines giving a combined methylation rate of 81.5% making it a common methylation target in MBs/PNETs (see Table 2 ). Fragment 4G78 on the other hand was hypermethylated in 80% (4/5) of the stPNETs and in the same number of cell lines, opposed to 47.5% (8/17) in MBs indicating a higher speci®city of methylation of this fragment for stPNETs. These ®ndings expand on our results reported recently demonstrating that MBs and stPNETs share certain methylation targets, but do also dier in a certain number of these. Our data con®rm previous data that MBs and stPNETs dier not only in their anatomical location, but also in the predominant genetic and epigenetic lesions detected in these tumors (Burnett et al., 1997; Russo et al., 1999) .
The consistent loss of two CpG fragments together might indicate the unlikely resolution of both NotI/ EcoRV fragments in the same RLGS pro®le, while the loss of three fragments together may indicate hypermethylation of a larger genomic region. The DNA fragments 2C35, 2C53, 3D35, 4F8 and 2E61 were lost together in eight tumors, and each possible triplet of these ®ve CpG islands was lost in at least 10 tumors together (see Figure 3a) . A test of concordance (see Statistical Methods) demonstrated signi®cantly correlated methylation for this`cluster' (P=0.045). Similar results could be demonstrated for clusters in which the fragments were methylated in a minority of samples. An example is the cluster of fragments 2F56, 3B36, 3B55 and 2E64. Our concordance test was highly signi®cant for this cluster (P50.001), supporting the notion that these DNA fragments may represent a set of CpG islands derived from the same chromosomal region (see Figure 3b) .
Nine of the total of 30 aberrantly methylated sequences have been cloned and partially sequenced. Table 3 gives a list of these fragments and their corresponding homologies. Interestingly methylation abnormalities were found at chromosomal regions that commonly show cytogenetic abnormalities in medulloblastomas such as chromosome 22q and 17p (Aldosari et al., 2000; FruÈ hwald et al., 2001; Lescop et al., 1999) . All sequenced clones demonstrated clearly the characteristics for CpG islands and six of the nine were associated with coding sequences, three of them characterized genes (see Table 3 ).
The aberrant methylation of certain CpG islands correlates with a dismal course of the disease
We sought to assess whether aberrant methylation might be a useful biomarker for MBs/PNETs and correlated the clinical data of our patients with the methylation status of certain DNA fragments. Neither the gender nor the age or the histological tumor subtype of our patients showed any signi®cant correlation with distinct methyla- Figure 4) . Surprisingly methylation of fragment 4C23 appeared to be associated rather with a better outcome than a dismal prognosis (P=0.032). The overall result of 8/30 (26.6%) nominally signi®cant fragments can be investigated rigorously. In 1000 permutation tests (see Material and methods) the maximum number of fragments achieving nominal P50.05 was 7. Moreover, the empirical Pvalues for the individual fragments accorded well with the asymptotic approximations. The results strongly suggests that the methylation pattern of several fragments aects survival, although the results for individual fragments awaits further con®rmation.
Discussion
Herein we have presented our evaluation of the biological and clinical importance of promoter methylation in medulloblastomas and other PNETs of the childhood CNS. The contribution of aberrant promoter methylation of the cell cycle regulator gene p15
INK4A and the tumor suppressor genes VHL, ECAD and TP53 to tumorigenesis is well established for multiple neoplasms (Baylin et al., 1998; Gra et al., 1995; Herman et al., 1994) . Similar data for medulloblastomas and other PNETs of the CNS are currently not available. MBs and stPNETs exhibit an aberrant global methylation pattern demonstrating tumor type speci®c and shared targets for methylation, a phenomenon also observed in other neoplasms . Extrapolated to the whole human genome, 1% of CpG islands may become methylated in primary MBs/PNETs and up to 6.3% in MB cell lines. This interesting and novel ®nding has far reaching consequences. First, methylated CpG islands may be used to detect novel genes involved in the pathogenesis of MBs/PNETs. The genes identi®ed in our study are a starting point only thus far. Second, aberrant methylation may hint towards chromosomal regions of particular interest harboring other genetic defects. For instance several DNA fragments appear to be methylated in combination, suggesting their derivation from the same chromosomal locus. This is not surprising as methylation may spread within a CpG island and may well expand over a large genomic region (FruÈ hwald et al., , 2001 . Recently, we demonstrated aberrant methylation of three dierent CpG islands dispersed over more than 360 kb in the center of the major breakpoint cluster region for medulloblastomas at 17p11.2 (FruÈ hwald et al., 2001) .
A risk adapted therapeutic approach is the basis for all successful cancer treatment strategies. This assessment is increasingly being performed by molecular analysis, as the conventional diagnosis by histology does not take the complex genetic nature of a heterogeneous group of tumors such as PNETs into account. Molecular markers have not been introduced into clinical strati®cation of patients but molecules such as TrkC and MYC are being considered for this purpose (Grotzer et al., 2000; Scheurlen et al., 1998) . We detected several CpG islands that might develop clinical potential, as their methylation was statistically associated with the outcome of the patients. It is clearly worthwhile to examine the CpG islands corresponding to the DNA fragments with a clinical correlation in a larger cohort and to determine if the methylation and/or mutation of associated genes might serve as an independent predictor of outcome. Once individual CpG islands are clearly identi®ed as being associated with a certain course of disease, patients can be evaluated by rapid and easy Ms-PCR analyses and grouped according to their methylation status.
Some childhood malignancies dier signi®cantly in their genetic makeup from their counterparts in adults, a ®nding that according to our data might also be true for changes at the epigenetic level. For example glioblastomas in children show very rarely mutations of the TP53 gene, which is very commonly mutated in adult tumors (Litofsky et al., 1994) . While and ECAD. The role of ECAD in brain tumors such as medulloblastomas is unclear. A recent immunohistochemical study did not detect expression of the ECAD protein in ®ve MBs (Schwechheimer et al., 1998) . The methylation seen in our samples is likely due to normal adjacent brain, as we ®nd complete methylation of the gene in the cell line D283 Med. Interestingly the ECAD gene is located at 16q22.1 a locus commonly deleted in MBs (Reardon et al., 1997; Russo et al., 1999) . Promoter methylation of p16 INK4A had not been described in medulloblastoma before and no mutations were detectable in a total of 30 medulloblastomas studied by independent investigators (Jen et al., 1994; Sato et al., 1996) . The ®rst indication for the involvement of the p16-Rb pathway came from the ®nding of homozygous deletions in two of 14 medulloblastomas (Barker et al., 1997) . Our ®ndings are particularly interesting in view of a recent publication demonstrating the development of medulloblastomas in transgenic mice with a knockout of TP53 and a deletion of the RB gene targeted to precursor cells of the external germinal layer in developing cerebellum (Marino et al., 2000) . The cell cycle regulator p16
INK4A is an integral part of the RB pathway and loss of 17p, the location of TP53, is a frequent event in medulloblastomas (Scheurlen et al., 1997) . It is thus tempting to speculate that a subset of medulloblastomas might be caused by a combination of defects in both, the TP53 and the RB, pathways.
The expression pattern for p16 in normal developing human cerebellum is unknown. In our study the positive control (normal urinary bladder) showed clear immunopositivity for p16, while all studied MBs and two normal cerebella were immunonegative. Recently, a similar discrepancy between immunohistochemistry and molecular data in the study of the p16 protein in glioblastomas was found. Here, 30% of the samples studied were negative for p16 despite the lack of proof for any molecular abnormality in the p16/RP pathway (Burns et al., 1998) . Immunohistochemical methods may thus not be sensitive enough for the evaluation of the role of p16
INK4A in malignancies such as MBs/PNETs. In conclusion we have examined MBs/PNETs for gene speci®c and overall methylation. We were able to exclude a number of well characterized methylation targets known from studies in adult cancers and detected several CpG islands associated with coding sequences as novel methylation targets. DNA methylation in MBs/PNETs holds great potential as a candidate mechanism for tumorigenesis and may turn out to be a very useful, rapidly assessable, long needed prognostic marker for patients with MBs/PNETs.
Materials and methods
Tissue samples and cell lines
Seventeen primary MBs and ®ve supratentorial PNETs (stPNETs) were analysed by RLGS. Fourteen were classic MBs, two desmoplastic MBs and one was not further classi®ed. One stPNET was a secondary tumor ocurring 1 year after chemo-and radiotherapy for a medulloblast- oma. Additional samples, not analysed by RLGS, were analysed by Ms-PCR. Patients were between 2 and 26 years of age (mean 7.8+2.8) and were 16 males and six females. Clinical follow-up of the patients ranged from 1 ± 6 years (mean 2.7+1.7 years) after diagnosis. Six patients have died, 15 are alive and one was lost to follow-up at the time of completion of the study. All other data are described in detail elsewhere . Tumor samples were obtained through the Cooperative Human Tissue Network (Pediatric Division). Control cerebellum DNA was from three boys (newborn, 4 years and 1 year) and one girl (11 years) all of whom had died from causes other the oncologic or neurologic in origin. The cell lines Daoy, D283 Med and D341 Med were obtained through ATCC (Rockland, MD, USA); MHH-MED-1 and MHH-PNET-5 were obtained from T Pietsch (Neuropathologisches Institut, UniversitaÈ t Bonn, Germany). Cell lines were grown as described (Sommer et al., 1999) . All procedures had been approved by the internal review board of Children's Hospital following the guidelines established by the NCI.
Isolation of nucleic acids
High molecular weight DNA was isolated according to published protocols . Total RNA was isolated using the Trizol reagent (Gibco, Grand Island, NY, USA). DNA and RNA qualities were assessed by gelelectrophoresis and spectrophotometry. 
Restriction Landmark Genomic Scanning (RLGS)
RLGS was performed according to published protocols . Brie¯y genomic DNA was blocked at sheared sites by the addition of nucleotide analogs (dGTPaS, ddTTP, ddATP and dCTPaS). The DNA was then cleaved with the methylation sensitive restriction enzyme NotI. The resulting protruding ends were labeled in a ®ll-in reaction. The labeled DNA was digested with EcoRV and 1.5 mg were electrophoresed in a 0.8% agarose tube gel (®rst dimension). The separated DNA fragments were cleaved ingel using HinfI and electrophoresed in a 5% polyacrylamide gel (second dimension). Finally the gels were dried and exposed to X-ray ®lm for 2 ± 20 days. RLGS pro®les derived from neoplastic cells were compared to pro®les from normal tissues (cerebella and PBL) by visual inspection .
Clone isolation and restriction mapping
NotI/EcoRV clones were isolated from a human genomic library previously established in our laboratory . Clones of interest were identi®ed using a catalogue of RLGS mixing pro®les .
Southern analyses
DNA methylation was con®rmed by Southern hybridization using the methylation sensitive restriction enzyme NotI in combination with EcoRV. 7.5 ± 10 mg of DNA were cleaved and separated on 0.8% agarose gels. Transfer to nylon membranes, hybridization and labeling of probe DNA was performed according to established protocols (Sambrook et al., 1989) . Probes for Southern hybridization were derived from the corresponding NotI/EcoRV clones.
Bisulphite treatment of genomic DNA
Genomic DNA was treated with sodium bisulphite as described (Herman et al., 1996) . Brie¯y 1 mg DNA was denatured with 3 M NaOH and then incubated at 508C overnight with 10 mM hydroquinone and 3 M sodium bisulphite. The DNA was then puri®ed using a Quiaquick gel extraction kit (Quiagen, Valencia, CA, USA). Finally the DNA was eluted from the spin columns using a buer containing 10 mM Tris-Cl, pH 8.5. The DNA was precipitated with 3 M sodium acetate and 100% ethanol, washed with 70% ethanol and then resuspended in 30 ml water. A total of 1 ml of this product was used in PCR assays.
Methylation specific PCR (Ms-PCR)
Methylation-speci®c PCR was performed as described by Herman et al. (1996) . Primers were modi®ed according to published studies or from promoter sequences in GenBank. All reactions were performed in a Perkin Elmer 9700 GeneAmp thermal cycler using Platinum Taq (Gibco) and buers as described elsewhere (Herman et al., 1996) . Initial denaturation of 958C for 10 h, was followed by 30 ± 35 cycles of 968C for 30 min, an annealing as indicated for each primer pair, and 728C for 1 min. DNA from a normal cerebellum (c1), arti®cially methylated with SssI methylase and the methyldonor S-adenosylmethionine following the suppliers recommendations (New England Biolabs, Beverly, MA, USA) served as a positive control. The same DNA (cerebellum) before in vitro methylation served as a negative control.
RT ± PCR analyses
Total cell line RNA was reverse transcribed using Thermoscript RT (Gibco) following the suppliers description modi®ed as reported previously . The quality of the resulting DNA was tested by ampli®cation with primers for the housekeeping gene glucose phosphate isomerase (GPI). PCR was performed as for MS-PCR with the respective conditions: GPI, GPIf 5'-GAC CCC CAG TTC CAG AAG CTG C-3' and GPIr 5'-GCA TCA CGT CCT CCG TCA CC-3' (178 bp, 608C for 15 min) p16-RTf 5'-GGA GAG GGG GAG AGC AGG CAG C-3', p16-RTr 5'-TGG CCC TGT AGG ACC TTC GGT GAC-3' (539 bp 688C for 15 min).
Immunohistochemistry for p16 protein MB and control paran sections were deparanized and subjected to immunohistochemistry using a multilink super sensitive detection kit (Biogenix, San Ramon, CA, USA). The tissue was treated with 3% hydrogen peroxide and Antigen Retrieval (Biogenix) in a microwave oven. Samples were blocked using Powerblock (Biogenix) and incubated in a 1 : 40 dilution of primary antibody to p16 (Calbiochem, Cambridge, MA, USA) overnight at 48C. After rinsing with Optima Wash (Biogenix), the sections were incubated in a multilink antibody against mouse for 20 min. The samples were then placed in label for 20 min. After another rinsing step, the samples were incubated at room temperature in AEC chromagen detection. Slides were then dried and covered with glass slips followed by analysis using a Nikon microscope.
SSCP analysis of p16
INK4a
Single strand conformation polymorphism (SSCP) analysis was performed for the three exons of the p16
INK4a locus. The following intronic primers were used: p16ex1f: 5'-GCT GGC TGG TCA CCA GAG-3' p16ex1r 5'-CCC TGC AAA CTT CGT CCT C-3', p16ex2f 5'-CCT GGC TCT GAC CAT TCT G-3', p16ex2r 5'-TTT GGA AGC TCT CAG GGT AC-3', p16ex3f 5'-ATG TGC CAC ACA TCT TTG AC-3' p16ex3r 5'-GGG GGA AGG CTT ATA TCT AC-3'. Reactions were performed in a PE 9700 thermal cycler using 1.25 U AmpliTaq Gold DNA polymerase with supplied PCR buer (Applied Biosystems, Foster City, CA, USA) containing 1.5 mM MgCl 2 , 10 pmol each primer, 100 mM dNTP, and 100 ng genomic DNA template in a total volume of 25 ml. PCR was performed with the following conditions: initial denaturation for 10 min at 958C, followed by 28 ± 32 cycles of 958C for 15 s, 568C (exon 3) or 608C (exon 1 and 2) for 15 s, and 728C for 1 min and a ®nal extension step at 728C for 5 min. PCR products were analysed as described on 12% polyacrylamide gels containing 7.25% glycerol and a twobuer system (Liechti-Gallati et al., 1999; Tanner et al., 1998) . Prior to loading 3 ml of PCR product were mixed with 2 ml of SSCP loading buer (0.2 M NaOH, 0.25% (w/v) bromophenol blue and xylene cyanol in formamide) and denatured at 958C for 6 min. PCR products were then visualized by standard silver staining. Sequence changes were identi®ed by shifts of double or single strand bands, or by generation of heteroduplexes.
Sequencing and database analysis
All sequence analyses were performed in the Core Facility of the Division of Human Cancer Genetics using an ABI PRISM 377 DNA sequencer. For CG-rich sequences high annealing temperatures were employed using an ABI PRISM BigDye Terminator Cycle Sequencing kit (Perkin Elmer, Foster City, CA, USA). NotI/EcoRV clones were sequenced with M13 forward and reverse oligonucleotides and by primer walking. DNA sequence ®les were analysed using DNAstar and Chromas software. For homology searches, sequences were analysed using BLAST at http:// www.ncbi.nlm.nih.gov/BLAST/.
Statistical methods
Statistical analyses were performed using Splus 4.5 (Mathsoft, WA, USA). Many of the tests involved multiple comparisons or summary statistics for which the null distribution is unknown. Thus we employed permutationbased tests for many of our results. Spearman rank correlation coecients were used to compare the methylation events in the cell lines to those averaged over the primary tumors. Because of the presence of many ties, a null permutation distribution was generated for the statistic. For each cell line, the correlation was computed for each of 10 000 simulations in which the methylation data were randomized across the CpG islands.
To detect the signi®cantly concordant methylation of fragments, a test was devised in which methylation events were summed over sets of fragments. This statistic shows a high variance across the samples for fragments that have concordant methylation patterns, and signi®cance testing compares the observed variance to that expected under chance.
Cox proportional hazards regression (Kalb¯eisch and Prentice, 1984) was used to compare individual methylation events to survival, with nominal signi®cance for each comparison determined by likelihood-based P-values. To account for multiple comparisons, regressions were also performed on the methylation data and 1000 random permutations of the survival times and accompanying censoring indicators. This approach preserves the correlation of methylation patterns within tumors, and enables computation of empirical P-values for the overall survival comparison, as well as for individual CpG islands.
